

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.*



## **GRANT OF SHARE OPTIONS**

This announcement is made pursuant to Rule 17.06A, Rule 17.06B and 17.06C of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors (the “**Director(s)**”) of MicroPort Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) has granted an aggregate of 11,648,808 share options (the “**Share Option(s)**”) under the share scheme adopted by the Company on 19 June 2023 (the “**Share Scheme**”) to 46 eligible participants (the “**Grantees**”), who are 44 employees (the “**Employee Participants**”) and two service providers (the “**Service Provider Participants**”) of the Group, subject to the acceptance of the Share Options by the Grantees, to subscribe for up to an aggregate of 11,648,808 ordinary shares of the Company (the “**Shares**”) of US\$0.00001 each, representing approximately 0.635% of the issued share capital of the Company as at the date of this announcement.

### **Details of the Share Options granted**

Date of grant	: 8 April 2024
Number of the Share Options granted	: An aggregate of 11,648,808 Share Options, each Share Option entitling the holder to subscribe for one Share at the exercise price
Exercise price of the Share Options granted	: HK\$6.58 per Share
Closing price of the Shares on the date of grant	: HK\$6.58 per Share

The average closing price of the Shares for the five trading days immediately preceding the date of grant	: HK\$6.29 per Share
Validity period of the Share Options	: Ten (10) years from the date of grant, i. e. from 8 April 2024 to 7 April 2034
Consideration for the grant	: US\$1.00 to be paid by the Grantees upon acceptance of the Share Options granted
Performance target and vesting conditions	<p>In respect of Employee Participants</p> <p>: (1) 5,949,016 Share Options granted shall vest and become exercisable on the first anniversary of the grant date;</p> <p>(2) 932,780 Share Options granted shall vest and become exercisable in the following manners: 50% of the 932,780 Share Options shall vest on 8 April 2026, and the remaining 50% shall vest in tranches on the 8<sup>th</sup> day of each month during the period from May 2026 to April 2028 (inclusive);</p> <p>(3) 4,098,320 Share Options granted shall vest and become exercisable on the fifth anniversary of the grant date;</p> <p>In respect of Service Provider Participants</p> <p>(4) 168,692 Share Options granted shall vest and become exercisable on the fifth anniversary of the grant date; and</p> <p>(5) 500,000 Share Options granted shall vest and become exercisable in equal installments on each of the first five anniversaries of the grant date;</p>

The purpose of the Share Scheme is to provide incentive to the eligible participants in order to promote the development and success of the business of the Group. The Share Options granted to the Grantees are awarded to them based on their work performance, historical and potential contributions and thus no additional performance target is imposed before the Share Options are vested to the Grantees. In view of the above, the remuneration committee of the Company considered the grant of Share Options aligned with the purpose of the Share Scheme.

- Clawback mechanism : The Share Options granted were subject to the clawback mechanism as set out in the terms of the Share Scheme, including but not limited to the lapse of the Share Options upon cessation of employment of the Grantees.
- Financial assistance : There is no arrangement for the Group to provide any financial assistance to the Grantees to facilitate the purchase of Shares under the Share Scheme.

#### Details of the Grantees

<b>Class of Grantees</b>	<b>Number of Share Options Granted</b>	<b>Approximate percentage of the issued share capital of the Company</b>
Employee Participants	10,980,116	0.599%
Service Provider Participant (1)	168,692	0.009%
Service Provider Participant (2)	500,000	0.027%
Total	<u>11,648,808</u>	<u>0.635%</u>

## **Service Provider Participants**

The purpose of the Share Scheme is to provide incentive to the eligible participant in order to promote the development and success of the business of the Group. The Share Scheme will give the eligible participant an opportunity to have a personal stake in the Company and will help motivate the eligible participant in optimizing their performance and efficiency and attract and retain the eligible participant whose contributions are important to the long-term growth of the Group. Service Provider Participant (1) is a family member of a Director and thus a connected person of the Company under Chapter 14A of the Listing Rules. Pursuant to Rule 14A.92(3)(a) of the Listing Rules, the grant of Share Options to such Service Provider Participant under the Share Scheme is fully exempt from Shareholders' approval, annual review and all disclosure requirements under Chapter 14A of the Listing Rules. The grant of the Share Options to Service Provider Participant (1) has been approved by the independent non-executive Directors pursuant to Rule 17.04(1) of the Listing Rules.

The Company is a leading medical device group focusing on innovating, manufacturing and marketing high-end medical devices globally.

The Service Provider Participants provide consulting services to the Company. Given that the services being provided by the Service Provider Participants are in areas that are desirable and necessary from a commercial or strategic perspective of the Group and help maintain or enhance the competitiveness of the Group, the Board believes that the grant of the Share Options to the Service Provider Participants can align its interests with the interests of the Company and the shareholders of the Company, motivate the Service Provider Participants to commit to the Company's future continued competitiveness, operating results and growth, and strengthen its long-term service commitment to the Company, and therefore serves the purposes of the Share Scheme.

## **NUMBER OF SHARES AVAILABLE FOR FUTURE GRANT**

After the above grant of Awards, 152,541,595 remaining Shares will be available for future grant under the existing scheme mandate limit of the Share Scheme, and 34,885,287 remaining Shares will be available for future grant under the service provider sublimit under the Share Scheme.

By Order of the Board  
**MicroPort Scientific Corporation**  
**Dr. Zhaohua Chang**  
*Chairman*

Shanghai, the People's Republic of China, 8 April 2024

*As at the date of this announcement, the executive director of the Company is Dr. Zhaohua Chang; the non-executive directors of the Company are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Ms. Weiqin Sun, Dr. Qiyi Luo and Mr. Bo Peng; and the independent non-executive directors of the Company are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.*

\* For identification purpose only